INOVIO PHARMACEUTICALS, INC. 8-K

What Happened
Inovio Pharmaceuticals, Inc. (INO) announced on July 29, 2026 that it entered an underwriting agreement with Piper Sandler for a public offering of 21,052,632 shares of common stock and accompanying warrants (or pre-funded warrants) priced as a unit at $0.95. The underwriter exercised its option to purchase additional warrants covering up to 6,315,788 shares. The offering is expected to close on or about July 31, 2026, and the company estimates net proceeds of approximately $18.3 million after fees and expenses.

Key Details

• Offering size: 21,052,632 shares and accompanying warrants to purchase up to 42,105,264 shares (each warrant covers two shares); underwriter exercised option for warrants covering up to an additional 6,315,788 shares.
• Pricing and exercise: Combined public offering price of $0.95 per share + warrant unit; warrant exercise price is $1.10 per share (warrants are immediately exercisable and expire five years from issuance). Pre-funded warrants are available in lieu of shares to address ownership limits.
• Ownership limits: Warrant exercises are subject to beneficial ownership caps (4.99%, 9.99% or 19.99%, as elected), with procedures (including use of pre-funded warrants) if a holder would exceed those caps.
• Underwriter and registration: Piper Sandler & Co. is the underwriter; the offering was made under the company’s Form S-3 registration statement declared effective July 10, 2026.

Why It Matters
This is a dilutive capital raise: the company is issuing new common stock and long‑dated warrants that could increase the share count if exercised. The expected net proceeds (~$18.3M) will add cash to Inovio’s balance sheet, but investors should note the potential for future dilution from exercisable warrants (immediately exercisable, five‑year term) and the ownership limitations that may lead to the issuance of pre‑funded warrants. The filing also includes customary underwriting and legal opinions and press releases announcing the offering.